Last ¥7,150 JPY
Change Today +100.00 / 1.42%
Volume 8.2K
4534 On Other Exchanges
Symbol
Exchange
Tokyo
Frankfurt
As of 12:53 AM 07/14/14 All times are local (Market data is delayed by at least 15 minutes).

mochida pharmaceutical co (4534) Snapshot

Open
¥7,080
Previous Close
¥7,050
Day High
¥7,170
Day Low
¥7,060
52 Week High
04/1/14 - ¥7,580
52 Week Low
12/25/13 - ¥5,678
Market Cap
156.6B
Average Volume 10 Days
19.7K
EPS TTM
¥489.04
Shares Outstanding
21.9M
EX-Date
09/26/14
P/E TM
14.6x
Dividend
¥150.00
Dividend Yield
2.24%
Current Stock Chart for MOCHIDA PHARMACEUTICAL CO (4534)

Related News

No related news articles were found.

mochida pharmaceutical co (4534) Related Businessweek News

No Related Businessweek News Found

mochida pharmaceutical co (4534) Details

Mochida Pharmaceutical Co., Ltd. engages in the production and sale of pharmaceuticals, diagnostic reagents, and skin care products. It provides cardiovascular agents, including Epadel for arteriosclerosis obliterans and hyperlipidemia; Atelec for hypertension; and Rocornal for angina pectoris. The company also offers antidiabetes agents, such as Fastic for diabetes; neurological agents, including Lexapro for depression, Grandaxin for autonomic dystonia, and Tecipul for depression; and anti-infectives, such as Florid for mycosis, Isoprinosine for subacute sclerosing panencephalitis, Beselna for condyloma acuminatum, and Francetin, an antibiotic, as well as Arasena-A for herpes zoster and herpes simplex encephalitis. In addition, it provides hormone preparations comprising Dinagest for endometriosis; Divigel for menopausal symptoms, such as hot flash treatment and hydrosis; Suprecur for endometriosis, precocious puberty, and uterine myoma; Desopan, an antiadrenal cortical hormone; Ortho 777-21/M-21, an oral contraceptive; Estriel for hormone replacement therapy and osteoporosis; and HCG Mochida, a human chorionic gonadotrophin injection. Further, the company offers biological preparations, such as Miraclid for acute circulatory failure and pancreatitis; Thrombin, a hemostatic agent; Novo-Heparin, an anticoagulant agent; and Uronase for acute myocardial infarction. Additionally, it provides diagnostic reagents for fertility/infertility, as well as CanD-Tec, a candida antigen detection test; face and body care, and hair care products; nutraceuticals; baby care products comprising bath oils, skin cleansers, and shampoos; and contract manufacturing services to other companies. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.

Founded in 1913

mochida pharmaceutical co (4534) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

mochida pharmaceutical co (4534) Key Developments

Mochida Pharmaceutical Co. Ltd., Annual General Meeting, Jun 27, 2014

Mochida Pharmaceutical Co. Ltd., Annual General Meeting, Jun 27, 2014.

Mochida Pharmaceutical Co. Ltd., 2014 Earnings Call, May 15, 2014

Mochida Pharmaceutical Co. Ltd., 2014 Earnings Call, May 15, 2014

Mochida Pharmaceutical Co. Ltd. to Report Fiscal Year 2014 Results on May 12, 2014

Mochida Pharmaceutical Co. Ltd. announced that they will report fiscal year 2014 results on May 12, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4534:JP ¥7,150.00 JPY +100.00

4534 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4534.
View Industry Companies
 

Industry Analysis

4534

Industry Average

Valuation 4534 Industry Range
Price/Earnings 14.7x
Price/Sales 1.5x
Price/Book 1.5x
Price/Cash Flow 15.9x
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MOCHIDA PHARMACEUTICAL CO, please visit www.mochida.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.